#USA #Boston #GenScript #Protein Expression #TurboCHO

GenScript Unveils TurboCHO™ Protein Expression Kit

In a significant advancement for the biotech sector, GenScript Biotech Corporation has recently launched its highly anticipated TurboCHO™ Protein Expression Kit. This next-generation reagent aims to set a new standard for the speed and efficiency of antibody production. Amidst the growing needs of the research community driven by high-throughput screening and AI-enabled technologies, this new kit promises to streamline the protein expression process dramatically.

Officials from GenScript, at the prestigious PEGS Summit in Boston, showcased their latest innovation. The TurboCHO™ kit is designed to produce high-quality research-grade antibodies and proteins, which are critical components in drug discovery and biologics development. One of its standout features is the ability to generate significant amounts of protein in as little as five business days, thus enabling researchers to obtain reliable and actionable data sooner.

"TurboCHO™ Protein Expression Kit delivers outstanding performance and unmatched value, putting powerful innovation within reach of every lab working to advance science," stated Sherry Shao, GenScript's Rotating CEO. This kit not only simplifies the complex process of protein expression but it also significantly supports efforts to bring new medications to patients more swiftly when every minute counts.

The introduction of this product is expected to impact labs of various sizes positively, making high-quality protein production accessible. The TurboCHO™ kit comes in two configurations:

• - Pro: Ideal for high-yield protein expression in a standard five-day timeframe, easily fitting into existing workflows.
• - Prime (Licensed): Delivers maximum speed with results that can be achieved as early as Day 3, allowing researchers to generate even higher yields.

Feedback from early adopters has been overwhelmingly positive, with many stating the TurboCHO™ kit offers the best-in-class experience in terms of speed and overall value. By surpassing competitors' typical timelines (which can extend to Day 10), the TurboCHO™ kit reduces the time researchers spend waiting for results, thereby facilitating faster decision-making processes. After purification cycles, users can enjoy yields up to three times higher, or five times with the Prime option.

A Game Changer in Drug Development

For researchers facing the increasing pressure of rapid discovery timelines, the implications of the TurboCHO™ kit’s performance are substantial. It enables quicker candidate selections and shortens the time needed for data acquisition, allowing teams to validate more drug candidates as they transition to experimental testing. This capability is especially crucial for the development of today's complex molecules.

"By delivering higher-quality antibody expression with dramatically faster time-to-data, we are eliminating a critical bottleneck in drug discovery," remarked Ray Chen, President of GenScript Life Science Group. By ensuring reproducibility and a seamless transition from screening to scaled production, GenScript is providing the tools necessary for testing various designs at a minimal cost while addressing the urgency of modern drug development.

As part of a broader innovation strategy, GenScript plans to continuously build upon this launch with enhancements in CHO cell lines and improved transfection systems, targeting scalable and automation-ready formats in future updates. This commitment positions the TurboCHO™ kit as a key player in redefining what’s possible in antibody expression processes.

The TurboCHO™ Protein Expression Kit is now available for purchase through GenScript’s direct sales channels and authorized distributors. To promote early adoption, GenScript is offering a limited-time introductory pricing along with comprehensive technical support for onboarding and workflow optimization. Adequate inventory exists to meet both domestic and international demand, ensuring that all interested labs can begin benefitting from this innovative solution right away.

For further details or to inquire about pricing, interested parties are encouraged to visit GenScript’s website directly.

About GenScript

Founded in 2002, GenScript Biotech Corporation has been at the forefront of innovation in the biotechnological landscape, providing essential tools for researchers and organizations aimed at developing transformative healthcare solutions. With over 6,100 employees serving more than 200,000 customers across the globe, GenScript continues to forge partnerships with academic institutions and industry leaders, collaborating on advancements that carry the potential to reshape service excellence in life sciences. Their mission remains clear: Make People and Nature Healthier Through Biotechnology.